These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26617867)

  • 1. Prognostic significance of HOXD13 expression in human breast cancer.
    Zhong ZB; Shan M; Qian C; Liu T; Shi QY; Wang J; Liu Y; Liu Y; Huang YX; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):11407-13. PubMed ID: 26617867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXD13 methylation status is a prognostic indicator in breast cancer.
    Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of ARID1B in breast invasive ductal carcinoma.
    Shao F; Guo T; Chua PJ; Tang L; Thike AA; Tan PH; Bay BH; Baeg GH
    Histopathology; 2015 Nov; 67(5):709-18. PubMed ID: 25817822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
    Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
    Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.
    Xu X; Tang X; Lu M; Tang Q; Zhang H; Zhu H; Xu N; Zhang D; Xiong L; Mao Y; Zhu J
    Exp Mol Pathol; 2014 Dec; 97(3):579-84. PubMed ID: 25445503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
    Tang J; Deng R; Luo RZ; Shen GP; Cai MY; Du ZM; Jiang S; Yang MT; Fu JH; Zhu XF
    Breast Cancer Res Treat; 2012 Jul; 134(2):549-60. PubMed ID: 22585231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.
    Cao YW; Li WQ; Wan GX; Li YX; Du XM; Li YC; Li F
    J Exp Clin Cancer Res; 2014 Nov; 33(1):97. PubMed ID: 25420528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.
    Buhmeida A; Dallol A; Merdad A; Al-Maghrabi J; Gari MA; Abu-Elmagd MM; Chaudhary AG; Abuzenadah AM; Nedjadi T; Ermiah E; Al-Thubaity F; Al-Qahtani MH
    Tumour Biol; 2014 Mar; 35(3):2817-24. PubMed ID: 24248542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
    Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
    BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
    Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
    Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOX D13 expression across 79 tumor tissue types.
    Cantile M; Franco R; Tschan A; Baumhoer D; Zlobec I; Schiavo G; Forte I; Bihl M; Liguori G; Botti G; Tornillo L; Karamitopoulou-Diamantis E; Terracciano L; Cillo C
    Int J Cancer; 2009 Oct; 125(7):1532-41. PubMed ID: 19488988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.
    Qian L; Gao X; Huang H; Lu S; Cai Y; Hua Y; Liu Y; Zhang J
    Oncotarget; 2017 Mar; 8(13):21444-21453. PubMed ID: 28423522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up.
    Donizy P; Pietrzyk G; Halon A; Kozyra C; Gansukh T; Lage H; Surowiak P; Matkowski R
    Oncol Rep; 2014 Apr; 31(4):1777-87. PubMed ID: 24535158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.
    Xiao J; Zhou Y; Zhu W
    Int J Clin Exp Pathol; 2015; 8(6):6458-65. PubMed ID: 26261522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
    Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
    Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ASMA
    Amornsupak K; Jamjuntra P; Warnnissorn M; O-Charoenrat P; Sa-Nguanraksa D; Thuwajit P; Eccles SA; Thuwajit C
    Clin Breast Cancer; 2017 Oct; 17(6):441-452.e2. PubMed ID: 28533055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relation of Parafibromin Expression with Clinicopathological Factors in Invasive Breast Carcinomas.
    Karaarslan S; Genç B; Nart A; Börekçi İ; Buğdayci MH
    Turk Patoloji Derg; 2016; 32(1):8-14. PubMed ID: 26832176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.